Comment on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment”

References

• Berger, M. L., Sox, H., Willke, R. J., Brixner, D.L., Eichler, H.G., Goettsch, W., Madigan, D., Makady, A., Schneeweiss, S., Tarricone, R., Wang, S.V., Watkins, J., and Mullins, D. C. (2017), “Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations From the joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making,” Pharmacoepidemiology and Drug Safety, 26, 1033–1039. DOI: 10.1002/pds.4297.
   PubMed Web of Science ®Google Scholar
• Chen, J., Ho, M., Lee, K., Song, Y., Fang, Y., Goldstein, B. A., He, W., Irony, T., Jiang, Q., van der Laan, M., Lee, H., Lin, X., Meng, Z., Mishra-Kalyani, P., Rockhold, F., Wang H., and White, R. (2021), “The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1883474.
   Web of Science ®Google Scholar
• Hernán, M. A., and Robins, J. M. (2017), “Per-Protocol Analyses of Pragmatic Trials,” New England of Journal of Medicine, 377, 1391–1398. DOI: 10.1056/NEJMsm1605385.
   PubMed Web of Science ®Google Scholar
• Hernán, M. A., and Robins, J. M. (2016), “Using Big Data to Emulate a Target Trial When a Randomized Trial is Not Available,” American Journal of Epidemiology, 183, 758–764.
   PubMed Web of Science ®Google Scholar
• Ho, M., van der Laan, M., Lee, H., Chen, J., Lee, K., Fang, Y., He, W., Irony, T., Jiang, Q., Lin, X., Meng, Z., Mishra-Kalyani, P., Rockhold, F., Song, Y., Wang H., and White, R. (2021), “The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1883475.
   Web of Science ®Google Scholar
• ICH E9 (R1). (2019), “ICH E9 (R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials.”
   Google Scholar
• Levenson, M., He,W., Chen, J., Fang, Y., Faries D., Goldstein, B. A., Ho, M., Lee, K., Mishra-Kalyani, P., Rockhold, F., Wang, H., and Zink, R. C. (2021), “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment, Statistics in Biopharmaceutical Research,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1883473.
   Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare (MHLW) (2021a), “Basic principles on Utilization of Registry for Applications, PSEHB/PED Notification No.0323-1 and PSEHB/MDED Notification No.0323-1,” March 23, 2021, available at https://www.pmda.go.jp/files/000240806.pdf.
   Google Scholar
• Ministry of Health, Labour and Welfare (MHLW) (2021b), Points to Consider for Ensuring the Reliability in Utilization of Registry Data for Applications PSEHB/PED Notification No.0323-2 and PSEHB/MDED Notification No.0323-2,” March 23, 2021, available at https://www.pmda.go.jp/files/000240807.pdf.
   Google Scholar
• Petersen M. L. (2014), “Commentary: Applying a Causal Road Map in Settings With Time-Dependent Confounding.” Epidemiology (Cambridge, Mass.), 25, 898–901. DOI: 10.1097/EDE.0000000000000178.
   PubMed Web of Science ®Google Scholar
• Petersen, M. L., and van der Laan, M. J. (2014), “Causal Models and Learning from Data: Integrating Causal Modeling and Statistical Estimation,” Epidemiology (Cambridge, Mass.), 25, 418. DOI: 10.1097/EDE.0000000000000078.
   PubMed Web of Science ®Google Scholar
• Research Team for AMED Research on the Regulatory Science of Pharmaceuticals and Medical Devices: Utilization of Real World Evidence Using Patient Registry Data to Support Regulatory Decision-Making. (2019), “Proposal on Assuring the Reliability of Patient Registry Data for Use in Application Dossiers of Pharmaceuticals and Medical Devices.” Japan Society of Clinical Trials and Research, 47(s1), s23–35.
   Google Scholar
• Shibata, T., and Research Team for AMED Research on the Regulatory Science of Pharmaceuticals and Medical Devices: Utilization of Real World Evidence Using Patient Registry Data to Support Regulatory Decision-Making. (2019), “A Background of Proposal on Ensuring the Reliability of Patient Registry Data for Use in Application Dossiers of Pharmaceuticals and Medical Devices,” Japan Society of Clinical Trials and Research, 47, S9–S12.
   Google Scholar
• Suissa, S., and Dell’Aniello, S. (2020), “Time-Related Biases in Pharmacoepidemiology,” Pharmacoepidemiology and Drug Safety, 29, 1101–1110. DOI: 10.1002/pds.5083.
   PubMed Web of Science ®Google Scholar
• Takeda, S., Shishido T., Yamamoto H., Haraguchi R., Sakurai T., Suzuki K., Hayashi K., Wada, K., Tachimori, H., Shibata, T., Ohmatsu, H., Tashiro, S., Nosaka, K., Sugiyama, Y., Yahagi, N., and Matsuyama A. (2017), “Research on the Strategy for Promoting Clinical Trials/Researches by Utilizing Disease Registration System (Patient Registry) Established by National Centers and Other Institutions,” Japan Journal of Medical Informatics, 37, 28–29.
   Google Scholar
• The Real-World Evidence Transparency Initiative Partnership, International Society for Pharmacoepidemiology (ISPOR), Duke-Margolis Center for Health Policy, and the National Pharmaceutical Council. (2019), “Draft White Paper: Improving Transparency In Non-Interventional Research for Hypothesis Testing—WHY, WHAT, and HOW: Considerations From the Real-World Evidence Transparency Initiative,” available at improving-transparency-in-non-interventional-research-for-hypothesis-testing_final.pdf (ispor.org).
   Google Scholar
• Tsiatis, A. A., Davidian, M., Zhang, M., and Lu, X. (2008), “Covariate Adjustment for Two-Sample Treatment Comparisons in Randomized Clinical Trials: A Principled Yet Flexible Approach.” Statistics in Medicine, 27, 4658–4677. DOI: 10.1002/sim.3113.
   PubMed Web of Science ®Google Scholar
• van der Laan, M. J., and Rose, S. (2011), Targeted Learning: Causal Inference for Observational and Experimental Data, New York: Springer Science & Business Media.
   Google Scholar
• Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., Gagne, J. J., Gini, R., Klungel, O., Mullins, C. D., Nguyen, M. D., Rassen, J. A., Smeeth, L., Sturkenboom, M.; joint ISPE-ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. (2017), “Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0,” Value Health, 20, 1009–1022.
   PubMed Web of Science ®Google Scholar
• Yue, L. Q., Lu, N., and Xu, Y. (2014), “Designing Premarket Observational Comparative Studies Using Existing Data as Controls: Challenges and Opportunities,” Journal of Biopharmaceutical Statistics, 24, 994–1010. DOI: 10.1080/10543406.2014.926367.
   PubMed Web of Science ®Google Scholar